Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Lundoch Diagnostics

Lundoch Diagnostics logotype.

Lundoch Diagnostics is developing an AI-based diagnostic tool using follistatin as a biomarker for type 2 diabetes. By imputing patented blood biomarker measurements, the program predicts type 2 diabetes many years before diabetes onset. 

Type 2 diabetes is a growing global epidemic, with 6% of the world population suffering from the disease. Early detection of type 2 diabetes risk before symptoms could help minimize health complications related to diabetes.

A large study led by Dr. Yang De Marinis, associate professor at Lund University, has identified a protein in the blood that could predict type 2 diabetes up to nineteen years before the onset of the disease. The study is published in Nature Communications.

To put the results into clinical use, Lundoch Diagnostics is commercializing the tool under patent applications in global markets, hoping to institute measures to prevent type 2 diabetes from becoming established.

Lundoch Diagnostics website

 

Lundoch Diagnostics

AI-based diagnostic tool using follistatin as a biomarker for type 2 diabetes.

Founded by Yang de Marinis.

Portfolio company since 2021.

Portfolio Manager LU Holding: eddie [dot] thordarson [at] innovation [dot] lu [dot] se (Eddie Thordarson), phone +46 70 874 99 02